Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This appears to be a chemotherapy combination regimen containing four different anticancer agents. The search results did not provide specific information about the exact combination of cyclophosphamide + mitoxantrone + paclitaxel + thiotepa together as a single regimen, but did offer details on individual components and their use in other combinations. Cyclophosphamide is an alkylating agent that works by damaging DNA and preventing cancer cells from dividing. Mitoxantrone is an anthracenedione antineoplastic agent that intercalates with DNA and inhibits topoisomerase II, preventing DNA repair and synthesis in cancer cells. Thiotepa is an alkylating agent that slows or stops the growth of cancer cells by interfering with DNA replication. Paclitaxel is a taxane that stabilizes microtubules, preventing cell division.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Cyclophosphamide + Mitoxantrone + Paclitaxel + Thiotepa.